Decoding PharmEasy’s latest down round logic
The proposed rights issue, at a 90% valuation cut, makes one thing clear: it’s the investors who are calling the shots here.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Internet
You may also like
Peak XV Partners should win the record outcome test with Pine Labs
Finally, this question will be answered. Who has returned the most amount of capital on any venture investment in India in the last two decades?
For equity investors, buy-at-any-price will fail
No matter how good a business, overpaying for a stock negatively impacts returns. Saurabh Mukherjea’s Marcellus is only the latest example of the perils of forgetting this timeless lesson.
Is Temasek a sovereign wealth fund?
Temasek is largely considered a sovereign wealth fund because it is set up by the Singapore government and invests in other companies. However, a few factors set it apart from other state investors.
